InNexus Biotechnology CEO To Present at the 11th Annual BIO CEO Conference

BRITISH COLUMBIA, CANADA - 4 February 2009 - InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, announces Jeff Morhet, Chairman and CEO, will be presenting at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 10:30-10:55 AM ET in the Park Ballroom at the Waldorf-Astoria in New York City.

Mr. Morhet will provide a brief corporate overview; discuss the company's growth and how its antibody enhancement technology improves the potency of existing and novel therapeutic products. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the symposium.

About BIO CEO

The 11th Annual BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies. The conference provides a neutral forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts have the opportunity to shape the future investment landscape of the biotechnology industry.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact:

Wade Brooksby

Chief Financial Officer

InNexus Biotechnology Inc.

480-862-7500